What gonadorelin is
Gonadorelin is synthetic gonadotropin-releasing hormone (GnRH), a decapeptide that stimulates pituitary release of luteinizing hormone (LH) and follicle-stimulating hormone (FSH). Its very short physiological signal is not interchangeable with long-acting GnRH agonists or antagonists, whose exposure patterns and clinical effects differ.
Names require care. Gonadorelin, gonadorelin acetate, and gonadorelin hydrochloride describe related active moieties or salts, but a salt name does not establish the formulation, route, strength, purity, or regulatory status of a finished product.
The U.S. Factrel claim needs a correction
The United States previously approved a human gonadorelin hydrochloride product, Factrel, for diagnostic evaluation of pituitary gonadotrope function under NDA 017925.[1] That human product is discontinued; current FDA DailyMed search results for gonadorelin show veterinary products, and the current Factrel label is explicitly an animal drug for cattle—not a human prescription label.[2][3]
Discontinuation does not erase the historical human evidence or by itself mean that FDA found the product unsafe. It does mean the site must not present today’s cattle product as a current human approval, and the historical approval does not transfer to a compounded or research vial.
What human studies can and cannot show
Gonadorelin stimulation can provoke measurable LH and FSH responses and remains used in some diagnostic settings outside the former U.S. product. A modern retrospective study of 67 males undergoing a GnRH stimulation test found that an FSHB promoter variant altered measured pituitary responses, illustrating that interpretation depends on biology and context.[4]
The diagnostic literature also documents limitations. An older study of 92 women found substantial response overlap across healthy and diseased groups and concluded that the quantitative response did not provide reliable diagnosis or prognosis by itself.[5] A hormone rise is a pharmacodynamic response, not proof of improved fertility, preservation of spermatogenesis during testosterone therapy, higher testosterone, better libido, or anti-aging benefit.
Pulsatile specialist therapy is not a generic protocol
Pulsatile GnRH has been investigated and used by specialist reproductive-endocrine services in selected hypothalamic disorders. Those regimens depend on confirmed diagnosis, delivery equipment, pulse timing, hormonal monitoring, fertility goals, and a known pharmaceutical product. They cannot be converted into a general subcutaneous wellness schedule.
Evidence involving gonadorelin in a diagnostic test or specialist pump cannot validate intermittent injections from an online vial, and evidence for a long-acting analogue cannot be transferred to short-acting gonadorelin.
Current uncertainty and product quality
Historical short diagnostic exposure reported transient effects such as flushing, headache, nausea, abdominal discomfort, dizziness, injection-site reactions, and occasional hypersensitivity. That experience is too limited to establish the safety of repeated, chronic, subcutaneous, or otherwise differently formulated use.
Compounded drugs are not FDA-approved, and FDA does not verify their safety, effectiveness, or quality before marketing.[6] With no current U.S. human Factrel product identified, a compounded or research gonadorelin vial should not be described as an approved equivalent. Teloryx therefore withholds a gonadorelin dose or reconstitution protocol.